More than 80% of people who inject drugs test positive for fentanyl—but only 18% intend to take it

More than 80% of New Yorkers who inject drugs test positive for the opioid fentanyl, despite only 18% reporting using it intentionally, according to a new study by researchers at the NYU School of Global Public Health.

The findings, published in the International Journal of Drug Policy, suggest that many people who inject drugs are unknowingly using fentanyl, which may increase their risk for overdose and potentially their tolerance to fentanyl if it is used over time.

In 2021, more than 100,000 people died of a drug overdose in the United States, with 66% of these deaths involving illicit fentanyl—a synthetic opioid that is 50 to 100 times more potent than morphine.

In New York City, drug overdose deaths have more than tripled since 2013 when fentanyl began to regularly appear in the illicit drug supply. Since 2017, fentanyl has been the most common drug involved in overdose deaths in New York City.

Research shows that people who take drugs may use fentanyl unintentionally, thinking that they are instead using heroin or another drug. However, more recent studies show that some people are aware of their fentanyl use and may seek out fentanyl or heroin mixed with fentanyl.

“As the proportion of drug overdose deaths involving fentanyl continues to increase, it’s important to monitor how often people are exposed to fentanyl and any changes in preference for fentanyl among people who use drugs,” said Courtney McKnight, clinical assistant professor of epidemiology at NYU School of Global Public Health and the study’s lead author.

To understand the pervasiveness of fentanyl use in New York City, McKnight and her colleagues conducted surveys and in-depth interviews in 2021 and 2022 with people who inject drugs. In the 313 surveys and 162 interviews, participants were asked about their drug use, including whether they used fentanyl intentionally in the last month, and their experience with overdoses. All survey participants underwent drug testing for fentanyl, heroin, other opioids, and stimulants so that researchers could compare toxicology results with self-reported drug use.

The toxicology results revealed widespread use of fentanyl among people who inject drugs in New York City. Fentanyl was the most common recently used drug, with 83% of participants testing positive for it (including 46% who tested positive for both fentanyl and heroin and 54% who tested positive for fentanyl without heroin). However, only 18% reported recently using fentanyl intentionally; most reported using heroin instead.

“The overwhelming majority of people in this study—regardless of intentionality of recent fentanyl use—reported heroin as their main drug, indicating a strong preference for heroin over fentanyl. Yet, as our urine toxicology data indicate, people who inject drugs seem to have little agency in avoiding fentanyl,” said McKnight, who is also a researcher with the Center for Drug Use at HIV/HCV Research at NYU School of Global Public Health.

Nearly one-quarter of participants had overdosed at least once in the previous six months, with 36% of those who intentionally used fentanyl experiencing a recent overdose, compared to 21% of those who reported no recent fentanyl use but tested positive for it, and 19% who reported no recent fentanyl use and tested negative for it. People who intentionally used fentanyl were also more likely to be younger, white, use drugs more often, and test positive for stimulants, among other characteristics.

In both the surveys and interviews, concerns about overdosing were common, with nearly all participants using strategies to prevent overdose, including keeping naloxone (a drug that can reverse an opioid overdose) nearby, using smaller amounts of drugs, using drugs around others, and having a trusted dealer.

“Nearly every person discussed the increased frequency of overdoses—a constant reminder of the lethality of the drug supply. A few said that the regularity with which overdoses were occurring in New York City was like nothing they had ever experienced,” said McKnight.

The interviews also revealed that people who inject drugs may be developing an increased tolerance to fentanyl, which may be driving a greater preference for the more potent drug. Several people interviewed reported that the potency of heroin has declined, which may indicate a developing but unintended tolerance to fentanyl that heroin can no longer address.

The researchers say the findings point to the need for scaling up existing evidence-based methods to prevent overdose deaths, such as naloxone distribution and increased access to medication for opioid use disorder. However, given the prevalence and deadliness of fentanyl, they stress that novel strategies to reduce overdoses should be considered, including increased support for and research on overdose prevention centers, and other forms of opioid maintenance treatments in which people who use drugs are prescribed opioids to avoid drugs tainted with fentanyl.

“New York City is home to the country’s first two legally sanctioned overdose prevention centers, which opened in 2021 and have already saved hundreds of lives, but more support and access to these programs are needed to further reduce overdose mortality,” said McKnight.

Additional study authors include ​​Allen Weng, Marley Reynoso, Sarah Kimball, Lily M. Thompson, and Don Des Jarlais of NYU School of Global Public Health. The research was supported by the National Institute on Drug Abuse (5R01DA003574-39). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

About the NYU School of Global Public Health

At the NYU School of Global Public Health (NYU GPH), we are preparing the next generation of public health pioneers with the critical thinking skills, acumen, and entrepreneurial approaches necessary to reinvent the public health paradigm. Devoted to employing a nontraditional, interdisciplinary model, NYU GPH aims to improve health worldwide through a unique blend of global public health studies, research, and practice. The School is located in the heart of New York City and extends to NYU's global network on six continents. Innovation is at the core of our ambitious approach, thinking and teaching. For more, visit: publichealth.nyu.edu

About CDUHR

The mission of the Center for Drug Use and HIV/HCV Research (CDUHR) is to end the HIV and HCV epidemics in drug using populations and their communities by conducting transdisciplinary research and disseminating its findings to inform programmatic, policy, and grass roots initiatives at the local, state, national, and global levels. CDUHR is a Core Center of Excellence funded by the National Institute on Drug Abuse (Grant #P30 DA011041).  It is the first center for the socio-behavioral study of substance use and HIV in the United States and is located at the NYU School of Global Public Health. For more information, visit www.cduhr.org.